

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5860443

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	APPOINTMENT OF INVESTIGATOR AS AGENT
CONVEYING PARTY DATA	
Name	Execution Date
HOWARD HUGHES MEDICAL INSTITUTE	10/06/2015
RECEIVING PARTY DATA	
Name:	REUBEN J. SHAW PH.D
Street Address:	SALK INSTITUTE FOR BIOLOGICAL STUDIES
Internal Address:	10010 NORTH TORREY PINES ROAD
City:	LA JOLLA
State/Country:	CALIFORNIA
Postal Code:	92037
PROPERTY NUMBERS Total: 3	
Property Type	Number
Application Number:	16269468
Application Number:	16389784
Application Number:	16389793
CORRESPONDENCE DATA	
Fax Number:	(650)493-6811
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(650) 493-9300
Email:	patentdocket@wsgr.com, hglasson@wsgr.com
Correspondent Name:	WILSON SONSINI GOODRICH & ROSATI
Address Line 1:	650 PAGE MILL ROAD
Address Line 4:	PALO ALTO, CALIFORNIA 94304
ATTORNEY DOCKET NUMBER:	49550-710.301,..302,401
NAME OF SUBMITTER:	HEATHER GLASSON
SIGNATURE:	/Heather Glasson/
DATE SIGNED:	12/10/2019
Total Attachments: 2	
source=710.301,302, 401 Appointment of Investigator as Agent_HHMI to Shaw#page1.tif	
source=710.301,302, 401 Appointment of Investigator as Agent_HHMI to Shaw#page2.tif	

APPOINTMENT OF INVESTIGATOR AS AGENT

Appointment by the HOWARD HUGHES MEDICAL INSTITUTE (the "Institute") of Reuben J. Shaw, Ph.D. an employee of the Institute, as its agent for the purpose of assigning certain rights to the SALK INSTITUTE FOR BIOLOGICAL STUDIES ("Salk").

WHEREAS, the Institute and Salk collaborate in the active conduct of medical research pursuant to an Agreement between them dated as of January 1, 1990 (the "Agreement");

WHEREAS, pursuant to the Agreement, the Institute has agreed to assign to Salk the Institute's rights with respect to inventions, discoveries, improvements, and other intellectual property, whether patentable or copyrightable (each a "Subject Property"), conceived or reduced to practice in the course of the research program conducted under the Agreement by employees of the Institute;

WHEREAS, research conducted pursuant to the Agreement by Reuben J. Shaw, Ph.D. while employed by the Institute at Salk has resulted in the invention of a certain Subject Property set forth in "NOVEL ULK1 INHIBITORS AND METHODS USING SAME," as set forth in an application for Letters Patent of the United States already filed on August 25, 2015, as PCT Patent Application No.: PCT/US2015/046777, designating the United States which claims the benefit of United States Provisional Application Nos. 62/184,212, filed on June 24, 2015 and 62/041,559, filed on August 25, 2014, respectfully;

and

WHEREAS, the Institute wishes Reuben J. Shaw, Ph.D. to act as its agent for the purpose of assigning to Salk the rights the Institute has in the Invention by reason of the research program conducted at Salk,

NOW, THEREFORE, the Institute hereby appoints Reuben Shaw, Ph.D. as its agent for the purpose of assigning the rights the Institute has or may acquire in the Invention by reason of the research program conducted at Salk to Salk in accordance with and subject to the conditions of the Agreement.

Executed 10/6/15


HOWARD HUGHES MEDICAL INSTITUTE



By: Erin K. O'Shea

Title: Vice President and Chief Scientific Officer

ATTESTED:



By: Heidi E. Henning

Title: Vice President and General Counsel